Supplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models

Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.